Business Context and Reporting Period
Company: TherapeuticsMD, Inc. (Nevada corporation, NASDAQ: TXMD)
Filing Type: Form 8-K (Current Report)
Date of Report: August 11, 2026
Reporting Period: Second Quarter ended June 30, 2026
Primary Purpose: Disclosure of financial results via Regulation FD (Item 7.01) and Results of Operations (Item 2.02).
Key Financial Metrics
The filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. The 8-K text itself does not provide specific values for the following metrics:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Investors must refer to the attached press release (Exhibit 99.1) for quantitative financial results.
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus the prior period. It only confirms the announcement of Q2 2026 results.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The Company expressly disclaims any obligation to release updates or changes to its expectations, events, conditions, or circumstances underlying forward-looking statements.
- Legal Status of Disclosure: Information in Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act, limiting liability for these specific disclosures unless expressly incorporated by reference elsewhere.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q2 2026 revenue, earnings, and cash flow figures.
- Verify if the press release contains updated financial guidance or operational milestones.
- Confirm the status of the Company's liquidity and debt obligations as detailed in the full press release.
- Note the Company's explicit disclaimer regarding future updates to forward-looking statements.